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Aim: To determine the prevalence of baseline/mean HbA1c among patients with suspected diabetes 
using Bio-Rad for the first time at a public hospital in Guyana. 
Methods: A retrospective, laboratory-based, descriptive study examined 1,547 diabetic patients who 
underwent repeat HbA1c testing at a public hospital laboratory in Guyana between 2010 and 2014. 
All statistical analyses were performed using SPSS 21.0, JMP and Microsoft Excel. Distributions were 
used to show frequencies, the bivariate fit test was done to achieve correlations and significance, the 
χ2 test was used to compare the differences in proportions and ANOVA was used for differences in 
mean differences. 
Results: A total of 1,547 patients were identified for the study. Mean age and standard deviation (SD) 
was 59.9 ± 11.47 (95% CI 59.3 - 60.4). Mean value for test 1 HbA1c was 9.2 ± 2.7 (95% CI 9.1-9.3), test 2 
HbA1c recorded 9.1 ± 2.5 (95% CI 8.9-9.2), test 3 HbA1c was 9.6 ± 2.6 (95% CI 9.3-9.9) and test 4 HbA1c 
recorded a mean of 9.6 ± 2.6 (95% CI 9.0-10.2). 
Conclusions: The mean HbA1c of the diabetic population was observed to be higher than the 
baseline in all tests. 
 (Kurup R, Deoraj M, Persaud S. Significance of HbA1c in Monitoring Diabetes at the Public Hospital, 
Guyana. SEEMEDJ 2019; 3(1); 60-68) 
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Introduction 
Diabetes mellitus is defined by the World Health 
Organization (WHO) as a chronic disease caused 
by inherited and/or acquired deficiency in the 
production of insulin by the pancreas (1). It is 
estimated that 39 million people are living with 
diabetes in the North America and the Caribbean 
(NAC) region (2). In 2014, there were 61,800 cases 
of diabetes in Guyana and diabetes was the 
cause of 1,025 deaths in adults aged 20-79. The 
International Diabetes Federation (IDF) also 
estimated that there are about 15,400 
undiagnosed cases of diabetes (3). With the 
prevalence of diabetes increasing at an alarming 
rate both nationally and internationally, 
diabetes-related complications and deaths tend 
to increase as well (4-8). It is therefore critical to 
maintain good glycemic control to keep 
diabetes in check and reduce diabetes-related 
complications (9). 
HbA1c has been recommended as a test option 
for the diagnosis of diabetes by both the 
American Diabetes Association (10) and the 
World Health Organization (WHO) (11). Both 
organizations advised that after a result 
consistent with the diagnosis of diabetes (≥ 6.5% 
(48 mmol/mol)), testing of HbA1c levels should 
be repeated in asymptomatic patients within 2 
weeks to rule out the rare occurrence of a 
sample being mislabeled. Not much research 
has been conducted in the area of repeat testing 
of HbA1c; however, Driskell et al. (2014) stated 
that “the optimal testing frequency required to 
maximize the downward trajectory in HbA1c was 
four times per year, particularly in those with an 
initial HbA1c of ≥7% (≥53 mmol/mol), supporting 
international guidance. Testing 3-monthly was 
associated with a 3.8% reduction in HbA1c 
compared with a 1.5% increase observed with 
annual testing; testing more frequently provided 
no additional benefit. Compared with annual 
monitoring, 3-monthly testing was associated 
with a halving of the proportion showing a 
significant rise in HbA1c (7–10 vs. 15–20%)” (12). 
The authors concluded that monitoring 
frequency is associated with a significant 
detrimental effect on diabetes control and that 
to achieve the optimum downward trajectory in 
HbA1c, monitoring frequency should be 
quarterly.  
 There are also reports that suggest that 
guidelines for testing HbA1c are not necessarily 
being followed (13-15). This study therefore 
evaluated for the first time the baseline/mean 
HbA1c (mmol/mol) among the Guyanese 
population and aims to determine if a standard 
international algorithm has been followed in 
regard to repeat testing of patients with 
suspected diabetes and of undiagnosed/high-
risk population. 
Methods  
This was a laboratory-based retrospective study 
conducted between 2010 and 2014 at a level III 
public hospital in Guyana. All patients who had 
already performed the HbA1c test to screen for 
diabetes and those who had complete 
information were included in the study. Any 
patient who did not follow the HbA1c algorithm 
was excluded. Inappropriate ordering of tests 
was defined as any order for testing a given 
patient occurring more than 3 months after the 
previous order. Bio-Rad D-10 was used to 
monitor HbA1c at the public hospital. Bio-Rad D-
10 utilizes the principle of High Performance 
Liquid Chromatography (HPLC) to determine the 
percentage of HbA1c. Permission to conduct this 
research was obtained from the Ethics 
Committee under the Ministry of Health, Guyana, 
and from the Director of Medical Services of the 
public hospital. 
 Data analysis 
The data collected from the database were first 
entered into a spreadsheet using Microsoft 
Excel. All statistical analyses were performed 
using SPSS 21.0, JMP and Microsoft Excel. 
Distributions were used to show frequencies, the 
bivariate fit test was done in order to achieve 
correlations and significance, the χ2 test was 
used to compare the differences in proportions 
and ANOVA was used for differences in mean 
differences. A p-value of < 0.05 was used to 
show significance. 
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Results 
A total of 1,547 eligible patients were selected 
for the study from the database of the GPHC 
medical laboratory. The patient population 
analysis had the following baseline 
characteristics: mean age was 59.9 ± 11.5 years 
(95% CI 59.3 - 60.4), 5% of the patients were 
between the ages of 21 and 40, 41% were 
between the ages of 41 and 60 and 54% were 
between the ages of 61 and 90.  
Figure 1 shows the HbA1c percentage in test 1, 
the maximum, median and minimum values of 
19.2%, 8.9% and 4.2% respectively and a mean 
and standard deviation of 9.2 ± 2.7. For the HbA1c 
percentage in test 2, the maximum, median and 
minimum values were 18.5%, 8.7% and 4.0% 
respectively, with a mean (SD) of 9.1 ± 2.5. For test 
3, 396 patients were tested with the maximum, 
median and minimum values of 19.7%, 9.4% and 
4.1% respectively, and a mean (SD) of 9.6 ± 2.6. 
Only 82 patients were tested for a fourth time, 
with the maximum, median and minimum values 
of 15.1%, 9.2% and 5.2% respectively, and a mean 





Figure 1. Distribution of HbA1c test results 
 
 
The mean HbA1c ± standard deviation (SD) of all 
tests is shown in Table 1. Test 1 had a mean of 
9.23 ± 2.6 (95% CI 9.1-9.4), Test 2 had a mean of 
9.08 ± 2.5 (95% CI 8.95-9.20), Test 3 had a mean 
of 9.59 ± 2.6 (95% CI 9.34-9.85) and Test 4 had a 
mean of 9.59 ± 2.6 (95% CI 9.01-10.17). 
Test 3 HbA1c % Test 4 HbA1c % 
Test 1 HbA1c % Test 2 HbA1c % 
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Table 1. Mean ± SD of HbA1c in regard to gender 
HbA1c 
Male 95% CI 
 
Female 95% CI 
 
Total 95% CI 
Mean ± SD Mean ± SD Mean ± SD 
Test 1 8.9 ± 2.7 8.7-9.2 9.4 ± 2.6 9.5-9.2 9.2 ± 2.7 9.1-9.4 
Test 2 8.7 ± 2.4 8.5-8.9 9.2 ± 2.6 9.4-9.1 9.1 ± 2.5 8.9-9.2 
Test 3 9.2 ± 2.5 8.7-9.7 9.8 ± 2.6 9.5-10.1 9.6 ± 2.5 9.3-9.8 
Test 4 8.8 ± 2.5 7.8-9.8 9.9 ± 2.7 9.3-10.7 9.5 ± 2.6 9.0-10.2 
 
The correlation analysis between each test is 
shown in Figure 2. The correlation between Test 
1 and Test 2, Test 3 and Test 4 was 0.64 (95% CI 
0.61-0.67), 0.58 (95% CI 0.50-0.64) and 0.66 (95% 
CI 0.52-0.77), respectively. The correlation 
between Test 2 and Test 3 was 0.64 (95% CI 0.57-
0.69), and the one between Test 2 and Test 4 
was 0.66 (95% CI 0.51-0.76). The correlation 
between Test 3 and Test 4 was 0.64 (95% CI 0.49-
0.75).
 
Figure 2. Correlation between individual HbA1c test values 
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Mean ± SD of each HbA1c test among male and 
female patients is shown in Table 2. Mean HbA1c 
was higher among females in all four HbA1c 
tests. Females were more at risk and all four 
tests indicated that females were above the 
and p < 0.05)).
 
Table 2. Prevalence of mean HbA1c and risk factor among male and female population 
  Female Male    Total  
HbA1c > 
Mean N (%) N (%) 
P-value RR (95% CI) N (%) 95% CI 
Test 1       
No 145 (9.4) 92 (0.1) < 0.05 1.13 (1.02-1.26) 237 (15.3) 13.6-17.2 
Yes 906 (58.6) 404 (26.1)   1310 (84.7) 82.8-86.4 
Test 2         
No 147 (9.5) 85 (0.1) < 0.05 1.04 (0.99-1.08) 232 (15) 13.3-16.9 
Yes 904 (58.4) 411 (26.6)   1315 (85.0) 83.1-86.7 
Test 3         
No 27 (6.8) 15 (3.8) > 0.05 1.04 (0.96-1.13) 42 (10.5) 7.9-13.9 
Yes 258 (64.7) 99 (24.8)   357 (89.5) 86.1-92.1 
Test 4         
No 3 (3.7) 2 (2.4) > 0.05 1.03 (0.90-1.16) 5 (6.1) 2.6-13.5 
Yes 53 (64.6) 24 (29.3)    77 (93.9) 86.5-97.4 
The mean difference ± standard error (SE) 
change between two HbA1c tests is shown in 
Table 3. The duration between individual tests is 
shown in Figure 3. Mean duration between test 1 
and test 2 was 16.14 ± 11.3 (95% CI 15.6-16.7), with 
the standard error of 0.28; for test 2 and test 3, it 
was 12.43 ± 8.83 (95% CI 11.6-13.3), with an SE of 
0.44; for test 3 and test 4, it was 10.25 ± 8.8 (95% 
CI 8.32-12.2), with an SE of 0.96.
 
Figure 3. Duration and standard error between individual tests 
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Table 3. Correlation and mean difference between each test 
HbA1c 
Mean 
difference SE 95% CI r 
Test 1 - Test 2 -0.15 0.05 -0.26-0.04 0.64 
Test 1 - Test 3 0.06 0.12 -0.17-0.29 0.57 
Test 1 - Test 4 0.22 0.23 -0.25-0.68 0.67 
Test 2 - Test 3 0.11 0.10 -0.10-0.32 0.63 
Test 2 - Test 4 -0.23 0.24 -0.70-0.23 0.67 
Test 3 - Test 4 -0.35 0.24 -0.83-0.12 0.65 
 
 
Of the 1,547 patients included in the study, for 
828 (53.5%) patients, the HbA1c result decreased 
in test 2 when compared to test 1. Of the 396 
patients who were tested for a third time, the 
HbA1c result decreased for 171 (43.2%) patients 
when compared to test 2. Of the 83 patients 
tested for a fourth time, 46 (56%) patients also 
experienced a decrease. 
 
Discussion 
The main outcome was the proportion of 
patients undergoing repeat HbA1c testing and 
the proportion of patients whose baseline HbA1c 
value decreased. This study used the HbA1c 
threshold for the diagnosis of diabetes (48 
mmol/mol (6.5%)), according to the new 
diagnostic criteria for diabetes adopted by the 
American Diabetes Association (16). 
This study represents the first attempt to review 
and analyze the HbA1c data of patients using 
Bio-Rad at the Georgetown Public Hospital 
Corporation. Older patients, between the ages of 
61 and 90, represented the largest group (54%) in 
the diabetic population and female patients 
were above baseline HbA1c in more cases than 
male patients. A similar pattern has been noted 
in other studies, where female patients of all age 
groups and races were found to be at risk (17).  
This study revealed that no standard guidelines 
were followed by the clinicians in terms of 
repeat testing intervals. There were many 
variations noted in regard to the duration 
between tests. Discordant HbA1c results have 
created confusion among the clinicians. 
Clinicians need to be aware that significant test-
retest variation exists in HbA1c and is sometimes 
quite large (18). Mean HbA1c for all four tests was 
recorded above 9.0, which is much greater than 
the baseline value. Many studies have warned 
that HbA1c concentrations above 48 mmol/mol 
(6.5%) are risk factors for development of 
diabetic retinopathy, macrovascular outcomes 
and death (18-21). 
The International Expert Committee (IEC) (24) 
and ADA (16) have proposed new diagnostic 
criteria for diabetes on the basis of HbA1c 
measurement, in which HbA1c of ≥ 6.5% is 
defined as diabetes. In the present study, an 
HbA1c level of 6.5% had a reasonably high 
specificity (99.1%) and low false-positive rate 
(0.9%) for the diagnosis of diabetes, which is in 
complete concordance with IEC and ADA 
recommendations.  
Repeat testing showed a significant decrease in 
HbA1c levels in a portion of patients. A decrease 
in a follow-up test is favored because this is 
indicative of following proper treatment 
strategies and overall control of the patient’s 
diabetic condition. It is also understood that a 
decrease should not be expected in every case 
of repeat testing, since an increased value 
maybe be accounted for by a number of 
different reasons. Multiple factors affect the 
accuracy of HbA1c as an indicator of average 
SEEMEDJ 2019, VOL 3, NO. 1 Significance of HbA1c in Monitoring Diabetes 
66 Southeastern European Medical Journal, 2019; 3(1) 
 
glucose concentration, including abnormal 
erythrocyte lifespan, assay-related artifacts, fast 
vs. slow glycosylation, ethnicity, pregnancy, use 
of drugs and acute illness. Different factors 
affect the validity of HbA1c, such as iron 
deficiency, altered hemoglobin structure, 
erythrocyte lifespan and interracial variability, 
age (the elderly and children), gender and 
pregnancy (25, 26).  
It is a well-known fact that high levels of HbA1c 
are associated with an increased risk of atrial 
tachyarrhythmia and paroxys¬mal atrial 
fibrillation in patients with type 2 DM (27). 
Furthermore, it has been reported that an 
increase of 1% in HbA1c concentration was 
associated with roughly a 30% increase in all-
cause mortality among diabetes patients (28). 
This shows that the proportion of HbA1c 
percentage increase is far too high and, as such, 
stricter measures should be implemented to 
reduce this percentage. 
 
Conclusion 
It is a fact that HbA1c is a test that is accurate and 
easy to administer for diagnosing diabetes, 
especially in low and middle income countries 
like Guyana. However, the mean HbA1c 
percentage of the diabetic population in Guyana 
was found to be 9.4%, which is far higher than 
ADA’s established HbA1c criteria for pre-
diabetes and diabetes (5.7% and 6.5%). 
Therefore, the researchers recommend that 
strict guidelines be followed by physicians in 
regular and accurate testing of HbA1c. 
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